ALLMedicine™ Acute Promyelocytic Leukemia Center

Jan 21st, 2022 - Acute promyelocytic leukemia (APL) is one of the most curable cancers. However, relapse of the disease is a difficult issue in clinical practice and it remains a great challenge that patients have a poor effect of conventional treatment in the cli...

Jan 15th, 2022 - For a number of years, oral cancer has remained in the top ten most common types of cancer, with an incidence rate that is steadily increasing. In total, ~75% oral cancer cases are associated with lifestyle factors, including uncontrolled alcohol ...

Jan 9th, 2022 - Acute promyelocytic leukemia (APL) is often accompanied by potentially fatal coagulopathy, especially in high-risk APL. Bleeding, particularly severe bleeding is the leading cause of early death (ED). Meanwhile, thrombosis, the other major coagulo...

Jan 7th, 2022 - NPM1 and FLT3-ITD are frequently mutated genes in acute myeloid leukemia. We studied clinico-hematological profile and survival outcome of adult acute promyelocytic leukemia (APL) patients harboring these mutations. De novo APL cases (> 12 years),...

Jan 7th, 2022 - Acute promyelocytic leukemia with Chediak-Higashi like giant granules.|2022|Zhang YH,Han X,|

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

Nov 12th, 2021 - This study includes 3 parts: during one part, enrolled participants will receive a single dose of IV ATO, and a week later a single dose of SY-2101 either in the fed or fasted condition, and a week after that, a single dose of SY-2101 in the fed o...

Jul 20th, 2021 - Although combined antiretroviral therapy (cART) could control human immunodeficiency virus type 1 (HIV-1) infection, the persistence of HIV-1 viral reservoir make it extremely difficult to achieving cure of AIDS. The shock and kill strategy has be...

Apr 6th, 2021 - PRIMARY OBJECTIVES: I. Assess whether a combination of all-trans retinoic acid (ATRA [tretinoin]), and arsenic trioxide (ATO) can produce long-term event-free survival in patients with low-risk untreated acute promyelocytic leukemia (APL). II. Ass...

Mar 25th, 2021 - PRIMARY OBJECTIVES: I. To decrease the total anthracycline dose from the best current published results in standard risk childhood acute promyelocytic leukemia (APL) while still maintaining a comparable event-free survival (EFS). SECONDARY OBJECTI...

Feb 17th, 2021 - The purpose of this study is to study the effect of an anticancer drug, Arsenic Trioxide, in patients with small cell lung cancer who have failed at least one standard chemotherapy regimen as well as patients who are unable to tolerate the standar...

Dec 14th, 2021 - Magrolimab plus combinations of various anti-leukemia therapies are being investigated for efficacy as options for frontline, relapsed/refractory, or maintenance treatment of patients with acute myeloid leukemia (AML), according to a poster presen...

Dec 12th, 2021 - The emergence of precision medicine has ushered in a groundbreaking era for the treatment of myeloid malignancies, with the ability to integrate individual molecular data into patient care. Over the past decade, insights from research focusing on.

Dec 6th, 2021 - A drug crucial for the emergency management of acute promyelocytic leukemia (APL) simply isn't stocked by many US hospitals, according to a recent report in the Journal of the National Comprehensive Cancer Network. The drug — all-trans retinoic ac...

Nov 19th, 2021 - The addition of quizartinib to standard induction and consolidation chemotherapy followed by quizartinib monotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival (OS) vs standard chemotherapy al...

Nov 15th, 2021 - "Remarkable" results with a novel treatment regimen in pediatric acute promyelocytic leukemia (APL) have been reported by researchers at the National Cancer Institute (NCI). Two-year event free survival (EFS) with the regimen was 98% and overall s...